A new trading day began on Friday, with Akero Therapeutics Inc (NASDAQ: AKRO) stock price down -5.61% from the previous day of trading, before settling in for the closing price of $29.76. AKRO’s price has ranged from $13.86 to $37.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -35.08%. With a float of $58.43 million, this company’s outstanding shares have now reached $69.80 million.
Let’s determine the extent of company efficiency that accounts for 56 employees. In terms of profitability, gross margin is 98.59%, operating margin of -94813.73%, and the pretax margin is -83528.87%.
Akero Therapeutics Inc (AKRO) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Akero Therapeutics Inc is 16.30%, while institutional ownership is 96.76%. The most recent insider transaction that took place on Nov 06 ’24, was worth 351,890. In this transaction Chief Development Officer of this company sold 10,000 shares at a rate of $35.19, taking the stock ownership to the 74,158 shares. Before that another transaction happened on Nov 06 ’24, when Company’s Officer proposed sale 10,000 for $32.74, making the entire transaction worth $327,400.
Akero Therapeutics Inc (AKRO) Earnings and Forecasts
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.99 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -35.08% per share during the next fiscal year.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Here are Akero Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 17.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.75, a number that is poised to hit -1.17 in the next quarter and is forecasted to reach -4.52 in one year’s time.
Technical Analysis of Akero Therapeutics Inc (AKRO)
Looking closely at Akero Therapeutics Inc (NASDAQ: AKRO), its last 5-days average volume was 0.73 million, which is a drop from its year-to-date volume of 0.87 million. As of the previous 9 days, the stock’s Stochastic %D was 5.61%. Additionally, its Average True Range was 1.81.
During the past 100 days, Akero Therapeutics Inc’s (AKRO) raw stochastic average was set at 47.59%, which indicates a significant increase from 11.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.18% in the past 14 days, which was higher than the 48.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $29.46, while its 200-day Moving Average is $25.11. However, in the short run, Akero Therapeutics Inc’s stock first resistance to watch stands at $29.72. Second resistance stands at $31.34. The third major resistance level sits at $32.68. If the price goes on to break the first support level at $26.76, it is likely to go to the next support level at $25.42. Should the price break the second support level, the third support level stands at $23.80.
Akero Therapeutics Inc (NASDAQ: AKRO) Key Stats
With a market capitalization of 1.85 billion, the company has a total of 69,799K Shares Outstanding. Currently, annual sales are 0 K while annual income is -151,760 K. The company’s previous quarter sales were 0 K while its latest quarter income was -72,710 K.
